USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ARTERIOCYTE, INC.
Address:
7100 Euclid Ave.
CLEVELAND, OH 44103-
Phone:
N/A
URL:
N/A
EIN:
200859825
DUNS:
191821342
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,090,593.00 4
SBIR Phase II $2,196,214.00 1
STTR Phase I $453,599.00 2
STTR Phase II $1,229,607.00 1

Award List:

Marrow-Derived Stem Cells for Coronary Artery Ischemia

Award Year / Program / Phase:
2005 / STTR / Phase I
Award Amount:
$142,954.00
Agency:
HHS
Principal Investigator:
Research Institution:
CASE WESTERN RESERVE UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of morbidity and mortality in the United States, accounting for approximately 1 million deaths per year. The objective of the Phase I pre-clinical studies outlined in this fasttrack STTR proposal is to validate the… More

Marrow-Derived Stem Cells for Coronary Artery Ischemia

Award Year / Program / Phase:
2006 / STTR / Phase II
Award Amount:
$1,229,607.00
Agency:
HHS
Principal Investigator:
Research Institution:
Case Western Reserve University
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of morbidity and mortality in the United States, accounting for approximately 1 million deaths per year. The objective of the Phase I pre-clinical studies outlined in this fasttrack STTR proposal is to validate the… More

CAN CD 133 CELLS PREVENT HYPOXIA DRIVEN RETINAL NEOVASCULARISATION IN A RODENT MO

Award Year / Program / Phase:
2007 / STTR / Phase I
Award Amount:
$310,645.00
Agency:
HHS
Principal Investigator:
Research Institution:
CLEVELAND CLINIC LERNER COLLEG
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The clinical significance of ocular angiogenesis is enormous, due to the fact that in the western hemisphere, retinal neovascularization resulting from diabetic retinopathy is the most common cause of new blindness in y oung patients, and choroidal… More

Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$281,794.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Critical Limb Ischemia (CLI) is a common problem that often results in major limb amputation. Circulating endothelial progenitor cells likely play a role in the pathogenesis of CLI; the number and function of these cell s that are mobilized from the bone marrow… More

Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$2,196,214.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Critical Limb Ischemia (CLI) is a common problem that often results in major limb amputation. Circulating endothelial progenitor cells likely play a role in the pathogenesis of CLI; the number and function of these cell s that are mobilized from the bone marrow… More

A Novel Expansion of Primary Leukemia Stem Cells

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$304,943.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Arteriocyte's long-term objective is to develop a platform for ex vivo expansion of leukemic stem cell (LSC) based on cytokine-enriched medium and the company's proprietary nanofiber culture scaffold (NANEX). Cancer ste m cell research is of significant… More

RAPID, HIGH VOLUME PRODUCTION OF RETICULOCYTES FOR P. VIVAX MALARIA RESEARCH

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$219,995.00
Agency:
HHS
Principal Investigator:
Adam M. Sorkin – 216-456-9669
Abstract:
DESCRIPTION (provided by applicant): Malaria results from infection by one of five species of mosquito-borne parasite. Each year, these protists infect 350-500 million worldwide and kill over one million people. Over three billion people living in tropicalregions are exposed to malaria every year.… More

Hematopoietic Reconstitution Using Ex Vivo Expanded Cord Blood CD34+ Cells

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$283,861.00
Agency:
HHS
Principal Investigator:
Stephen E. Fischer – 617-794-2711
Abstract:
DESCRIPTION (provided by applicant): Umbilical cord blood (UCB) provides unique advantages over bone marrow (BM) and mobilized peripheral blood (MPB) as a source of hematopoietic stem cells (HSCs) for transplants, as it allows use of partially HLA-matchedunits without increasing GvHD incidence.… More